doi: 10.3389/fnut.2025.1534000 Received 25 November 2024 Accepted 11 March 2025 Published 09 April 2025 Volume 12 - 2025 Edited by Luciana Mosca, Sapienza University of Rome, Italy Reviewed by Runnan Grace Li, University of Kentucky, United States Flores Naselli, University of Palermo, Italy Di Zhu, Chi Forest (Beijing) Food Technology Group Co., Ltd., China Updates Copyright 2025 Rana, Katiyar, Arun, Berrios and Kumar
The key differences lie in dosage, regulation, and clinical validation
In some cases, doctors may adjust the dose of semaglutide or recommend medication to help control acid reflux symptoms
Mounjaro and Zepbound contain tirzepatide, a dual GLP-1/GIP agonist
Researchers found no link between GLP-1 exposure before or early in pregnancy and major birth defects or fetal complications